PhUSE EU Connect 2018

Handling CRF design changes in a live environment

by Nieke de Ruiter & André Snelting (both OCS)

Building an EDC database is based on the study protocol which should contain all required information for the eCRF. Precision, consistency, and completeliness are highly important for that. In many situations these criteria are not met. In other scenarios the protocol demands a high level of complexity from the EDC design. For example, study procedures can be country or site specific, or a combination of paper and electronic diaries is used. These aspects and challenges should be taken into account when reviewing the protocol. Even when the protocol fulfils these criteria, and the protocol is not overly complex, change requests in the production phase cannot be avoided but are often time consuming and error prone. This paper provides a number of examples of change requests to the eCRF and the database and describes how these were implemented. In addition, lessons learned about smart design changes will be shared and discussed.

The use of SDTM standards for non-submission purposes

by Lieke Gijsbers (OCS) & Paul Vervuren (Nutricia Research B.V.)

Driven by the growing need for the aggregation of clinical trial data, Nutricia Research started the implementation of CDISC SDTM for their early life nutrition studies, and initiated a conversion project for their legacy studies. One of the challenges faced is that current CDISC standards do not entirely address the complex and diverse nature of data collected in nutrition studies, such as gastrointestinal tolerance and intake of infant formula as study product together with a breastfeeding reference group. A combination of domains is sometimes required to represent data from a single source dataset. Since 2015, Nutricia Research and OCS Life Sciences have been working together on the definition of specific SDTM domains and jointly built expertise in the legacy data conversion of early life nutrition data. This paper presents concrete examples and implementation solutions from this project, and reflects on possibilities and limitations of using SDTM as a standard for non-submission purposes.

A proprietary, CDASH/SDTM-hybrid data model to expedite clinical data review

by Lieke Gijsbers (OCS) & Tom Van Der Spiegel (Janssen Pharmaceutica N.V.)

In 2016 Janssen identified the need to expedite clinical data review. A proof of concept demonstrated the value of pursuing a new and proprietary data model for data review, serving as single source of truth. The Data Review Model (DRM) that was introduced is strongly based on CDISC CDASH and SDTM. DRM provides full traceability and describes both clinical and operational (system) data consistently across studies. On the longer term, the pharmaceutical company plans to implement a metadata-driven environment, including data conversion from source data into DRM. In 2017, OCS Life Sciences and Janssen piloted DRM by implementing a mapping framework that supports both documentation and execution of source to target data mapping. This paper describes how multiple trials were mapped to support the pilot phase of DRM, to learn, refine and document the value of DRM prior to moving to production implementation.